Video

Dr. Twelves on the Value of the Iniparib Trial Results

Author(s):

Christopher Twelves, MD

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Related Videos
Idoroenyi Amanam, MD
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD
Margaret E. Gatti-Mays, MD, MPH, FACP
Domenica Lorusso, MD, PhD
Martin H. Voss, MD
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD
Related Content
FDA
October 11th 2024

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Sunil Adige, MD
October 10th 2024

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Joseph A. Sparano, MD, of Mount Sinai
October 7th 2024

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29